Individuals of African ancestry in the United States and Europe are at increased risk of developing schizophrenia and have poorer clinical outcomes. The antipsychotic clozapine, the only licensed medication for treatment-resistant schizophrenia, is under-prescribed and has high rates of discontinuation in individuals of African ancestry, due in part to increased rates of neutropenia. The genetic basis of lower neutrophil levels in those of African ancestry has not previously been investigated in the context of clozapine treatment. We sought to identify risk alleles in the first genome-wide association study of neutrophil levels during clozapine treatment, in 552 individuals with treatment-resistant schizophrenia and robustly inferred African genetic ancestry. Two genome-wide significant loci were associated with low neutrophil counts during clozapine treatment. The most significantly associated locus was driven by rs2814778 (β = −0.9, P = 4.21 × 10
Introduction
The incidence of psychotic disorders is increased in migrant populations [1, 2] . In particular, individuals of African and African-Caribbean ethnicity in the United Kingdom and African-American ethnicity in the United States are at especially high risk of developing schizophrenia [3, 4] . The exact causes of this are unknown, but are at least in part due to factors associated with being a member of a disadvantaged minority, such as socioeconomic stress and isolation [5, 6] . Those of African and African-Caribbean ancestry have also been consistently demonstrated to have poorer clinical outcomes including higher rates of inpatient admissions involving the police or compulsion [7, 8] . Furthermore, a recent study examining cases of first-episode psychosis in the United Kingdom found that in comparison with White British patients, Black African and Black African-Caribbean patients had a worse long-term clinical course with lower rates of recovery [8] .
The antipsychotic clozapine is the only licenced treatment for those with schizophrenia who fail to respond to other antipsychotics (termed treatment-resistant schizophrenia) [9, 10] . While clozapine has been robustly demonstrated to reduce the risk of rehospitalisation and to be associated with better symptomatic and functional outcomes in treatment-resistant schizophrenia [11] , it is widely under-prescribed. Clozapine is particularly underutilised in those of African-American ethnicity in the United States and Black African or African-Caribbean ethnicity in the United Kingdom [12] [13] [14] , populations that have also been consistently associated with a higher rate of clozapine discontinuation [15, 16] . This is at least partly due to increased rates of neutropenia in those of African ancestry while taking clozapine [17, 18] . Neutropenia is defined as an absolute neutrophil count less than 1500 cells/mm 2 , while agranulocytosis is diagnosed if the neutrophil count is below 500 cells/mm 2 and is a severe condition that can endanger life. Clozapine treatment increases the cumulative risks of neutropenia (3.8%) and agranulocytosis (0.8%), which has led many countries to introduce regulatory systems for frequent blood monitoring while on the medication [19] .
Recent evidence has indicated that genetics plays a role in susceptibility to neutropenia and agranulocytosis on clozapine. Genetic association studies have implicated HLA-DQB1 and HLA-B variants in European and Japanese populations [20] [21] [22] , and rs149104283, a singlenucleotide polymorphism (SNP) intronic to transcripts of hepatic transporter genes SLCO1B3 and SLCO1B7 [22] , in individuals of European ancestry. Reflecting a general dearth of clinical and genetic research in non-European populations, all studies to date investigating clozapineassociated neutropenia have focussed predominantly on individuals of European ancestry, limiting the generalisability of findings. This is particularly relevant to those of African ancestry who are known to have lower baseline neutrophil counts on average compared to those from other populations [23] . In this study, we report the first genome-wide association study (GWAS) of neutrophil levels during treatment with clozapine in individuals with treatment-resistant schizophrenia and robustly inferred African genetic ancestry.
Methods

Sample
Individuals included in this study were from the CLOZUK2 sample, all of whom were prescribed clozapine in the United Kingdom with a clinician diagnosis of treatment-resistant schizophrenia. The samples were acquired anonymously in partnership with Leyden Delta (Nijmegen, The Netherlands), a company that supplies and monitors clozapine in the United Kingdom, as part of the CRESTAR collaborative project (www.crestar-project.eu). The project has received UK National Research Ethics Service approval and was in accordance with the UK Human Tissue Act. All samples were anonymised and linked with blood monitoring data provided from clozapine blood monitoring databases. Full details of the CLOZUK2 sample are provided elsewhere [24] .
Neutrophil data
The neutrophil count for each individual was defined as the lowest absolute neutrophil count (ANC) on record during clozapine treatment within the blood monitoring database held by Leyden Delta, who retain all historical blood results within their monitoring system. All individuals were started on clozapine after fulfilling baseline criteria including a baseline neutrophil count above 2000 cells/mm 2 . For clarity, the terms "ANC" and "neutrophil count" are used interchangeably. All results of ANC < 1500 cells/mm 2 , indicating neutropenia and the standard threshold that triggers discontinuation of clozapine in the United Kingdom, were confirmed by either (a) a consecutive ANC < 1500 cells/mm 2 or (b) two or more results of ANC < 2000 cells/mm 2 before or after the index result. We excluded individuals who in the opinion of their treating clinician had an alternative explanation for neutropenia such as concomitant immunosuppressive medication (n = 4).
Genotype quality control and imputation
The CLOZUK2 sample was genotyped by deCODE Genetics (Reykjavik, Iceland) on the Illumina HumanOmniExpress-12 chip. PLINK v1.9 [25] was used for genotype quality control following standard protocols [26] . Maximum per-individual and per-marker missingness were set at 2%, and individuals with inbreeding coefficients (F) higher than 0.2 were removed from the dataset. After this curation process, 7287 individuals genotyped at 698,442 markers remained in the dataset.
Genotype imputation was performed using the Haplotype Reference Consortium panel and the pipeline offered by the Michigan Imputation Server [27, 28] . As this pipeline allowed for imputation of autosomes only at the time this study was conducted, genotype data from the X chromosome were imputed on the Cardiff University RAVEN cluster [29] using the SHAPEIT/IMPUTE2 algorithms [30] and a combination of the 1000 Genomes phase 3 (1KGPp3) and UK10K reference panels [31] . Both approaches to genotype imputation have been shown to produce compatible results and to perform similarly in terms of accuracy for variants with minor allele frequencies (MAFs) larger than 1% [27] . After imputation, 20 million SNPs with INFO scores higher than 0.8 remained in the dataset.
Defining genetic ancestry
In order to select a cohort of individuals with African genetic ancestry, we stratified the CLOZUK2 individuals using Ancestry Informative Markers (AIMs), routinely employed in the field of forensic genetics [32] . The use of AIMs has been shown to be an efficient way of inferring biogeographical ancestry [33, 34] , which reflects the genetic association of an individual to a particular continental or sub-continental population group. As these groups are broadly defined and show relatively large genetic differentiation [35] , this approach circumvents the problems associated with several other approximations to genetic ancestry [36] , such as self-reported ethnicity [37] or country of origin [38] . Our analysis of AIMs in the CLOZUK2 identified 566 individuals of Sub-Saharan African ancestry, of whom 552 had complete neutrophil count and covariate data, which we term CLOZUK2-AFR. Details on the procedure used to select these individuals are provided in the Supplementary Methods.
Post-imputation curation of the CLOZUK-AFR genotype data
From this sample, a total of 13.5 million SNPs were taken forward for analysis after applying a MAF filter of 1% and a Hardy-Weinberg Equilibrium (HWE) filter of P ≤ 1 × 10
. HWE tests were carried out using the exact "mid-p" test implemented in the "HardyWeinberg" R package [39] , as this test is valid for both autosomal and sex-linked markers. Relatedness was assessed using the PC-Relate approach, which identified 18 pairs of relatives (π ≥ 0.2). For analyses sensitive to confounding by including related individuals, such as contingency table tests, we excluded one random member of each of these pairs. Otherwise, all individuals were included.
Association analysis of neutrophil count
Imputed data from the CLOZUK2-AFR individuals were analysed using the linear mixed model (LMM) implemented in GCTA v1.26 [40] , specifically the "leave-one-chromosome-out" procedure [41] . Genotype relatedness matrices, needed to control for population stratification and family structure in LMM frameworks, were calculated directly from the genotyped SNPs. Covariates used in the analyses included gender, age (at lowest ANC), age 2 and total days on clozapine treatment. The total number of days on clozapine treatment was not associated with neutrophil count. PLINK v1.9 [25] was used to identify index SNPs in approximate linkage equilibrium (r 2 = 0.1) using the linkage disequilibrium (LD)-clumping procedure, with a p value cut-off of 10 −4 and a distance cut-off of 3000 kb. Conditional analyses to further identify independent index SNPs were carried out using the GCTA-COJO procedure [42] .
Imputation and analysis of human leucocyte antigen (HLA) alleles
Previous research into clozapine-associated neutropenia has highlighted polymorphisms of the HLA system as drivers of adverse drug reactions in schizophrenia [21] . In order to investigate these, we imputed HLA classical alleles using the software HIBAG v1.12 [43] (see Supplementary Methods for further details). Association testing of the HLA classical alleles used linear regression of dosages weighted by imputation probabilities, following Levin et al. [44] .
Covariates employed matched the GWAS described before, though we added the first 5 principal components calculated by PC-AiR [45] to correct for potential population stratification.
Results
Absolute neutrophil count in African individuals
A GWAS of lowest ANC during treatment with clozapine in a total of 552 individuals of African ancestry ( Fig. 1 ; Supplementary Figure 1 , λ GC = 0.985) identified six independent SNPs (r 2 < 0.1) that were associated at the genome-wide significance level of P < 5 × 10 −8 ( Table 1) . Five of these SNPs were in close proximity at a locus (1q23.2) tagging, among others, atypical chemokine receptor 1 (ACKR1), classically called the Duffy antigen receptor complex (DARC).
The most significantly associated SNP in that locus was rs2814778 (β = −0.86, P = 4.21 × 10
), which is a regulatory variant in the ACKR1 promoter region. None of the other SNPs remained genome-wide significant after a mixed model analysis conditional on rs2814778, indicating this SNP is responsible for the association signal of the entire locus (Supplementary Figure 2) . The other genome-wide significant signal was rs77198048 (β = 1.63, P = 8.95 × 10
) an intronic variant (MAF = 1.07%) of the zinc finger protein 618 (ZNF618) gene on chromosome 9 (9q32). Our sample size had 80% power to detect a β ≥ 1.06 for alleles with MAF ≥ 5% at the genome-wide significance level of P < 5 × 10 −8
, and 98% power to detect the association of a variant with similar MAF and effect size to rs2814778.
rs2814778 genotype effect on neutrophil counts
We examined the effects of the different rs2814778 genotypes on ANC after excluding 18 related individuals who were included in the mixed model analysis, leaving 534 CLOZUK2-AFR in the sample. Of these, 419 individuals were homozygous for the C (African) allele, 106 were heterozygous and 9 homozygous for the T (European) allele. The Mann-Whitney test (P = 0.099) did not show significant ANC differences between CT and TT individuals, supporting previous evidence that the C allele has a recessive effect on neutrophil counts [46] . Thus, for all further analyses we combined individuals with TC and TT genotypes. Figure 2a displays the distribution Fig. 1 Manhattan plot of the lowest ANC GWAS in the CLOZUK2-AFR sample. The genome-wide significant peak at chromosome 1 corresponds to the ACKR1 locus mentioned in the text Columns represent variant name (SNP), chromosome (CHR), base position (BP), risk allele (A1), frequency of the risk allele (A1 frequency), beta co-efficient (Beta), standard error (SE) and association P value of neutrophil counts during treatment with clozapine by rs2814778 genotype in our African ancestry sample. Individuals with the CC genotype had a median lowest ANC of 1900 /mm 2 compared to 2900 /mm 2 for CT/TT individuals (P = 3.55 × 10
−24
). Figure 2b is a density plot showing the ANC distribution in different CLOZUK2 ancestry subsets (Supplementary Methods; Supplementary Table 5), stratified by rs2814778 genotype. While the difference between CC and CT/TT individuals is clearly shown, the CC neutrophil distributions are similar among Sub-Saharan Africans and North Africans (Kolmogorov-Smirnov test P = 0.941). Similarly, the neutrophil distributions of CT/TT groups show no difference between Sub-Saharan Africans and all other ancestries (Kolmogorov-Smirnov test P = 0.234, see Fig. 2b ).
Given these results we then tested explicitly whether the rs2814778 Duffy-null genotype is more informative of ANC than genetic ancestry, using generalised linear modelling (Supplementary Methods). A model including genetic ancestry (European or African) and the GWAS covariates explained 8.29% of the variance in ANC. When the rs2814778 genotype was added to this model, the variance explained increased to 10.94%, and genetic ancestry was no longer associated with ANC. The removal of genetic ancestry resulted in a statistically equivalent model (likelihood ratio test P = 0.794) indicating that the rs2814778 genotype is more informative of ANC than genetic ancestry. Adding the second GWS SNP (rs77198048) to this model also resulted in a statistically equivalent model (likelihood ratio test P = 0.182). Analogous results were obtained by fitting these models to predict neutropenia (ANC < 1500 cells/mm 2 ) in our sample, which yielded a maximum explained variance of 13.03%.
A total of 83 (19.81%) CC individuals had neutropenia during treatment with clozapine (ANC < 1500 /mm 2 ) in comparison to 2 (1.74%) individuals with a T allele ( Table 2 ). In both the United States and United Kingdom, thresholds of ANC below which alterations in clozapine monitoring and management are indicated have been defined based on normative values from European populations. In the United Kingdom, ANC results below 2000 /mm 2 mandate closer monitoring and more regular blood testing, whereas ANC < 1500/mm 2 requires clozapine treatment to be withdrawn. All study individuals who developed neutropenia had clozapine immediately discontinued, although some were later rechallenged. We used Barnard's exact test to estimate the effect size of rs2814778 on crossing these thresholds, given their important clinical implications. CC individuals are much more likely to develop an ANC < 2000 /mm 2 (odds ratio (OR) = 6.84, 95% confidence interval (CI) = 4.13-13.67, P = 2.90 × 10 ) than T allele carriers. We could not test genotype-mediated differences at lower ANC thresholds, due to the absence of CT/TT carriers.
rs2814778 and benign ethnic neutropenia
There are regulatory mechanisms in place in the United States and United Kingdom to lower the neutropenia threshold at which clozapine has to be discontinued for those deemed to have benign ethnic neutropenia (BEN), a hereditary condition characterised by mild, chronic neutropenia [47] [48] [49] [50] . Of the 74 individuals in our sample with a formal diagnosis of BEN provided by a Consultant Haematologist, 72 (97.30%) have the CC genotype for rs2814778 (Table 2) . Considering the safety and clinical outcomes of the 83 individuals with a CC genotype and ANC < 1500 cells/mm 2 , a total of 80 were rechallenged with clozapine. Of these, at the time of data collection 75 (93.75%) were still maintained on treatment, 4 (5.0%) had subsequently discontinued and 1 had died (1.25%, unrelated to ANC). It is not valid to test the sensitivity and specificity of rs2814778 as a predictive test for BEN in this sample due to the lack of systematic screening for BEN. 
Association of rs77198048
The second genome-wide significant polymorphism was rs77198048 on chromosome 9 (Table 1 ). This signal comes from a single intronic SNP with no known function and there were no other SNPs in LD (r 2 > 0.6) from this region in our sample (or on the 1000 genomes African reference genomes). However, we were not able to identify any reasons related to population stratification or admixture (Supplementary Figure 3) , which would suggest that this finding is an artefact. None of the 10 individuals who had the minor T allele had neutropenia (ANC < 1500 cells/mm 2 ), and thus we could not reliably statistically test the impact on neutropenia case/control status.
Association analysis of HLA alleles
Using the HIBAG pipeline, we were able to impute 11 HLA-DQB1 classical alleles and 21 HLA-B classical alleles at MAF > 1% in the CLOZUK2-AFR sample; none were significantly associated with ANC after Bonferroni correction for multiple testing (P < 0.05/32 = 1.56 × 10 ).
Assessment of previous findings from European populations
We were unable to impute any of the following variants implicated in recent association studies of clozapineassociated neutropenia in European populations due to the risk alleles being absent or very rare in CLOZUK2-AFR; rs149104283 (intronic to transcripts of SLCO1B3 and SLCO1B7) [22] , the HLA-DQB1 candidate SNP rs113332494 [22] or the HLA-DQB1 (126Q) and HLA-B (158T) amino acid polymorphisms [21] .
Discussion
In the first genetic association study of neutrophil counts during clozapine treatment in individuals of African ancestry, we identify two genome-wide significant loci. The most significant association is attributable to rs2814778 (P = 4.21 × 10
), a regulatory variant in ACKR1 which has previously been associated with lower neutrophil counts in individuals of African ancestry, and is thought to be causal for BEN. We demonstrate that in those taking clozapine, individuals homozygous for the C allele for rs2814778, also known as the Duffy-null genotype, are substantially more likely (OR = 20.36) to be classified as having neutropenia (ANC < 1500 cells/mm 2 ), the threshold at which clozapine must be stopped. Our results indicate the relevance of the rs2814778 genotype for those taking clozapine and its potential as a pharmacogenetic test, dependent on the outcome of additional safety studies, to assist decision making in the initiation and on-going management of clozapine treatment.
The rs2814778 Duffy-null genotype had a frequency of 78% in our study population of UK people with African ancestry and has an~65% frequency in African Americans [51] (Supplementary Table 6 ). In those of African ancestry, it has been robustly implicated in white blood cell and neutrophil counts in several large meta-analyses [46, [51] [52] [53] . It is also considered to be the cause of BEN [48] , a hereditary condition characterised by low neutrophil counts which occurs in 25-50% of individuals with African or Middle Eastern ancestry [47] [48] [49] [50] . In support of rs2814778 as causal for BEN, over 97% of individuals diagnosed with BEN in our study were homozygous for the C allele. For those on clozapine, we show that rs2814778 genotype is a better predictor of low ANC than ancestry. Furthermore, the distribution of neutrophil counts closely followed genotype at rs2814778 regardless of ancestry (African, European and South-West Asian) (Fig. 2b) . Given that rs2814778 is the 15 weeks after onset of clozapine treatment leading to clozapine discontinuation. The individual was rechallenged with clozapine 3 days later and did not have any further agranulocytosis results, though did develop additional neutropenia (ANC < 1500 cells/mm 2 ). The patient was still being successfully maintained on clozapine treatment when the data were extracted for this study likely cause of BEN, this study implies that BEN is not adequately diagnosed in individuals treated with clozapine. Indeed, this is demonstrated by our finding that only 59% of those with the CC genotype and an ANC between 1000 and 1500 cells/mm 2 had a clinical BEN diagnosis. Indirect evidence also supports the hypothesis that BEN is underdiagnosed; BEN had a much lower frequency (14%) in our sample than expected from its prevalence of 25-50% in healthy populations of African ancestry [47] [48] [49] [50] . Furthermore, the rates of BEN diagnosis in this sample will be overestimated given its cross-sectional nature (at the point of sample collection), which enriches for those who have been rechallenged with clozapine. Others have similarly noted under-representation of BEN in smaller samples of people of African ancestry taking clozapine [14] .
The Duffy-null rs2814778 (C) allele disrupts an erythroid transcription factor GATA-1 binding site in the promoter of ACKR1 and, as a result, the erythrocytes of homozygote rs2814778 carriers do not express the ACKR1 protein [54] . Erythrocytes lacking this Duffy antigen are refractory to the malaria parasite Plasmodium vivax infection and hence the Duffy-null variant confers an evolutionary advantage [55] . Recent experimental work in mice has shown that ACKR1 deficiencies during early haematopoiesis do not result in reduced production of neutrophils, rather neutrophils exhibit altered phenotypic characteristics that result in their preferential loss from blood by egressing into tissues, particularly via migration to the spleen, thus causing neutropenia [56, 57] . Importantly, there is good evidence that BEN does not lead to increased rates of infection or clozapine-associated agranulocytosis [17, 18, 58] . In light of this, for patients with a diagnosis of BEN, clozapine monitoring thresholds in the United Kingdom are reduced to ANC > 1500 cells/mm 2 and ANC < 1000 cells/ mm 2 for initiation and discontinuation, respectively. The recently implemented Clozapine Risk Evaluation and Mitigation Strategy (REMS) program in the United States also allocates BEN patients separate monitoring thresholds of ANC > 1000 cells/mm 2 for initiation and ANC < 500 cells/mm 2 for discontinuation. Our study supports the safety of separate thresholds for those with BEN; 94% of rs2814778 C homozygotes with ANC < 1500 cells/mm 2 were successfully maintained on clozapine treatment after reinstatement. However, in clinical practice, the process of diagnosing BEN is challenging, particularly for those who may be acutely psychotic at the point of clozapine initiation or as a result of clozapine withdrawal. In the United Kingdom and the United States, a BEN diagnosis is made by a specialist in haematology after assessing the individual's ancestral background, drug history and the presence of stable low neutrophil counts in the absence of infection. All this necessitates referral by psychiatrists, attendance at haematology outpatient clinics, further blood sampling and review. In light of these practical considerations, it is perhaps unsurprising that only a minority of those who have treatment-resistant schizophrenia and who are eligible for a BEN diagnosis actually receive it, and then go on to have appropriate management with clozapine [14] .
Our results indicate that genotyping rs2814778 may offer a simple but sensitive alternative strategy for the diagnosis of BEN. In the context of clozapine treatment, individuals who are homozygous for the C allele and who do not show signs of compromised immune function could have revised neutrophil thresholds in line with current BEN monitoring procedures. This ability to prospectively lower acceptable neutrophil thresholds could address the underutilisation of clozapine in those of African ancestry by (i) enabling more of those suitable for clozapine to start the medication given a lower baseline threshold, and (ii) avoiding disruption of treatment for those who discontinue clozapine and may or may not under current arrangements be subsequently diagnosed with BEN. In addition to identifying BEN, rs2814778 could also avoid misclassification; the two individuals who had a BEN diagnosis but did not have the Duffy-null genotype in this study have likely been diagnosed incorrectly and could therefore be at increased risk of agranulocytosis. It is not known how many people are denied clozapine due to neutrophil levels that fall below the permitted threshold for initiation (ANC > 2000 cells/mm 2 ); however, we do know that a pre-treatment analysis of neutrophil levels would not have identified the individuals in this study who would have benefitted from such a test. Furthermore, the potential applications could extend beyond those of African ancestry given rs2814778 occurs at nontrivial rates in other populations in which malaria has been historically endemic, including some parts of the Middle East, South-West Asia and Oceania (Supplementary Table 6 ) [59] .
Further studies are required prior to the implementation of Duffy-null genotype testing to confirm its safety and utility both in prospectively determining BEN status and also to investigate the risk of agranulocytosis when rechallenging Duffy-null patients, though it is reassuring that our cross-sectional data and other currently available evidence support the safety of such approaches [17, 18, 58] . We envisage that the genetic test could be conducted by clinical or commercial laboratories with DNA sampling being added to the current pre-treatment screening procedures for clozapine, which includes blood testing, once regulatory approval is in place. Recent studies suggest that current genotyping procedures for determining Duffy-null status are both robust and reproducible, and thus their implementation in the context of a clinical blood monitoring service should be straightforward [60, 61] .
It is important to note that the Duffy-null genotype is the main causal factor for the Duffy-null phenotype (classically termed "Fy(a-b-)") [59, 62] . Recent studies have shown that direct genotyping is the best available method to identify Duffy-null individuals in the context of neutropenia [60, 61] , since in the isolated handful of reported cases with Duffy-null phenotype in the absence of the rs2814778 mutation, neutropenia is not observed [63] . A further challenge to using Duffy-null phenotyping arises from other ACKR1 mutations causing weak antigen expression which can mimic the Duffy-null phenotype causing serological ambiguity, resulting in misclassification of up to 3.5% of individuals depending on the population [60, 62, 64] . For this reason, we argue that genotyping of rs2814778 would outperform the serological typing of the Duffy-null phenotype.
The second genome-wide significant finding corresponds to an intronic variant in the ZNF618 gene, which has been characterised as a contributor to methylation and chromatin binding of epigenetic regulators [65] . Given this association comes from a single SNP rs77198048 with no known function, we interpret it with caution. Though we were not able to identify any specific reasons to suggest that this finding is an artefact, independent replication is required to confirm this result.
The Duffy-null association we report in this study adds to existing evidence from our group and others, which together indicate three potential pathways to clozapineassociated neutropenia: (i) immune-mediated [20] [21] [22] , (ii) hepatic transport and potentially drug toxicity [22] and (iii) genetic factors that cause benign neutropenia causally unrelated to clozapine. In summary, we provide novel insights into the genetic architecture of neutrophil counts during clozapine treatment in individuals with African genetic ancestry. In the first genome-wide association study of neutrophil levels during clozapine treatment, we demonstrate strong association with rs2814778, a regulatory variant in the ACKR1 gene that has also been described as the genetic basis for BEN. We suggest that rs2814778 genotyping offers an opportunity for personalised medicine in psychiatry, although crucially we recognise that further research is needed to establish the safety, acceptability, uptake, clinical utility and the practical outcomes and costbenefits of such a test.
Data Archiving
The code used to run the analysis is available from the authors upon request. The GWAS summary statistics are available from: http://walters.psycm.cf.ac.uk/.
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